Human Third Set of Teeth Regrowth: Kyoto University Gene Therapy Enters Clinical Trials

Japanese researchers at Kyoto University have made a monumental stride in regenerative dentistry with their innovative approach to tooth regrowth, targeting the activation of a potential third set of teeth in humans. This breakthrough, stemming from years of meticulous research published in prestigious journals, centers on suppressing the USAG-1 protein to unleash dormant tooth buds. Led by Katsu Takahashi, a senior lecturer at Kyoto University's Graduate School of Medicine, the project has progressed from animal models to human clinical trials, marking a pivotal moment for higher education-driven biomedical innovation in Japan.

Understanding Human Tooth Development and the Third Dentition

Humans, like many mammals, possess a diphyodont dentition system, featuring two successive sets of teeth: primary (deciduous or baby teeth) and permanent teeth. Unlike polyphyodont species such as sharks or reptiles that continuously replace teeth, human evolution suppressed a third set, leaving latent tooth buds that occasionally manifest as supernumerary teeth in about 1-4% of the population. These dormant structures, if activated, could revolutionize treatment for tooth loss affecting over 2.3 billion people globally, per World Health Organization estimates.

At Kyoto University, researchers delved into the genetic regulators of odontogenesis—the process of tooth formation. Tooth development begins in embryonic stages through interactions between epithelial and mesenchymal tissues, orchestrated by signaling pathways like bone morphogenetic protein (BMP), Wnt, and fibroblast growth factor (FGF). Disruptions lead to conditions like oligodontia (congenital absence of six or more teeth) or anodontia (total absence), impacting oral health, nutrition, and quality of life.

The Discovery of USAG-1: A Key Suppressor in Tooth Formation

The breakthrough originated from identifying uterine sensitization-associated gene-1 (USAG-1), a protein that binds to BMP and LRP5/6 (low-density lipoprotein receptor-related protein 5/6), inhibiting essential signals for tooth morphogenesis. Kyoto University teams demonstrated that USAG-1 knockout in mice resulted in supernumerary teeth, highlighting its regulatory role.

In a landmark 2021 study published in Science Advances, Takahashi and colleagues developed monoclonal antibodies specifically neutralizing USAG-1's interaction with BMP, avoiding broad Wnt disruption to minimize side effects. This precision approach restored tooth formation in genetic models of agenesis. The paper, affiliated with Kyoto University's Graduate School of Medicine and collaborators from the University of Fukui, underscored the potential for cell-free therapies bypassing stem cell complexities.

Groundbreaking Animal Studies Paving the Way

Preclinical validation spanned multiple models. In Runx2-deficient mice (mimicking cleidocranial dysplasia with tooth agenesis), local USAG-1 siRNA application rescued arrested tooth germs, promoting development. Antibody injections in EDA mutant mice generated whole supernumerary molars, confirmed via micro-CT imaging.

• Enhanced BMP signaling via phosphorylated Smad1/5/8 upregulation.
• Ferrets, with human-like diphyodonty, developed extra incisors post-treatment, mirroring potential human outcomes.
• No significant adverse effects, supporting safety for translation.

These findings, detailed in Kyoto University repositories, built a robust foundation for clinical advancement. For academics interested in similar translational research, opportunities abound in Japan's vibrant research jobs sector.

Photo by Matthew Moloney on Unsplash

Transition to Human Clinical Trials: Phase 1 at Kyoto University Hospital

Clinical trials commenced in September 2024 at Kyoto University Hospital, a testament to the university's integration of basic research and clinical application. Phase 1, sponsored by Toregem Biopharma, enrolls 30 healthy males aged 30-64 missing at least one molar, administering the anti-USAG-1 antibody TRG-035 intravenously to assess safety and pharmacokinetics over 11 months.

Lead investigator Katsu Takahashi, head of dentistry at Kitano Hospital and Kyoto affiliate, envisions this as fulfilling dentists' dreams. Subsequent phases target pediatric patients aged 2-7 with severe oligodontia. As of early 2026, trials continue without reported halts, with Phase 2 efficacy studies slated for 2025-2026.Mainichi report on trial start

Key Research Publications Driving the Innovation

Kyoto University's output includes pivotal papers:

• Science Advances (2021): "Anti-USAG-1 therapy for tooth regeneration through enhanced BMP signaling" – First demonstration of antibody-induced tooth recovery in mutants.
• Scientific Reports (2021): Local Usag-1 siRNA promotes regeneration in Runx2-KO mice.
• Regenerative Therapy (2024): Advances in tooth agenesis therapies, emphasizing autologous regeneration.

These publications, accessible via Kyoto's KURENAI repository, exemplify Japan's higher education emphasis on high-impact biomedical research. Aspiring researchers can explore postdoc positions in such labs.

Stakeholder Perspectives: Researchers, Dentists, and Patients

Takahashi's motivation stems from patient suffering: "We want to help those with tooth loss." Dental associations praise the potential to reduce implant reliance, costing billions annually. Patients with congenital defects express hope, though ethicists note access equity concerns in Japan's universal healthcare.

Collaborators like Toregem Biopharma bridge academia-industry gaps, fostering innovation ecosystems vital for Japanese universities.

Challenges, Risks, and Ethical Considerations

Potential risks include off-target BMP activation causing ectopic bones or tumors, though animal data shows specificity. Long-term immunogenicity of antibodies requires monitoring. Ethical debates surround pediatric trials and equitable distribution post-2030 commercialization.

• Safety: No major issues in Phase 1 interim.
• Efficacy variability: Dependent on residual tooth bud viability.
• Regulatory: Orphan drug status for oligodontia accelerates approval.

These hurdles underscore the rigorous training in Japanese higher ed programs.

Photo by James Pere on Unsplash

Implications for Global Dentistry and Higher Education

Success could slash $500B+ global dental market reliance on prosthetics, improving mastication and health. For higher ed, it highlights regenerative medicine's rise, with Kyoto University exemplifying interdisciplinary excellence. Explore career advice for dentistry academia or Japan university jobs.

Future Outlook and Opportunities in Japanese Academia

By 2030, TRG-035 may enable routine tooth regrowth, spawning spin-offs. Kyoto University continues related research, offering avenues for university jobs in biomed. This positions Japan as a regenerative therapy leader, attracting international talent. For career growth, check higher ed jobs, career advice, and rate my professor for insights.